Lista de obras - Carmen Fava - Dominio Público Uruguay

A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients.

artículo científico publicado en 2011

Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis.

artículo científico publicado en 2008

Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.

artículo científico publicado en 2017

BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation.

artículo científico publicado en 2015

BCR-ABL1 mutation ≠ ponatinib resistance

artículo científico publicado en 2016

Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia?

artículo científico publicado en 2010

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib

artículo científico publicado en 2011

Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey

scientific article published on 18 June 2020

Concomitant occurrence of BCR-ABL and JAK2V617F mutation

scientific article published on 01 September 2011

Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib

scientific article published on 25 June 2011

Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor

artículo científico publicado en 2016

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

artículo científico publicado en 2013

Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia

artículo científico publicado en 2016

HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC)

artículo científico publicado en 2011

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome

artículo científico publicado en 2016

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study

artículo científico publicado en 2013

Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

artículo científico publicado en 2012

Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemia.

artículo científico publicado en 2009

Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia

artículo científico publicado en 2014

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

artículo científico publicado en 2015

Milestones and monitoring

artículo científico publicado en 2015

Molecular Resistance: An Early Indicator for Treatment Change? ⬇️

artículo científico publicado el 28 de enero de 2012

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

artículo científico publicado en 2011

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

artículo científico publicado en 2009

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors

artículo científico publicado en 2012

Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia.

artículo científico publicado en 2014

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series

artículo científico publicado en 2017

Ponatinib for chronic myeloid leukaemia: future perspectives

artículo científico publicado en 2016

Reduced Expression of Sprouty1 Contributes to the Aberrant Proliferation and Impaired Apoptosis of Acute Myeloid Leukemia Cells

scientific article published on 04 July 2019

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.

artículo científico publicado en 2018

Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant.

artículo científico publicado en 2013

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib

artículo científico publicado en 2017

The choice of first-line chronic myelogenous leukemia treatment

artículo científico publicado en 2015

The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia.

artículo científico publicado en 2017

The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia

artículo científico publicado en 2015

Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia

artículo científico publicado en 2016

Update on emerging treatments for chronic myeloid leukemia.

artículo científico

Lista de obras de Carmen Fava

A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients.

Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis.

Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.

BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation.

BCR-ABL1 mutation ≠ ponatinib resistance

Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia?

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib

Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey

Concomitant occurrence of BCR-ABL and JAK2V617F mutation

Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib

Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia

HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC)

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study

Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemia.

Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

Milestones and monitoring

Molecular Resistance: An Early Indicator for Treatment Change? ⬇️

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors

Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia.

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series

Ponatinib for chronic myeloid leukaemia: future perspectives

Reduced Expression of Sprouty1 Contributes to the Aberrant Proliferation and Impaired Apoptosis of Acute Myeloid Leukemia Cells

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.

Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant.

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib

The choice of first-line chronic myelogenous leukemia treatment

The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia.

The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia

Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia

Update on emerging treatments for chronic myeloid leukemia.